Cyberonics gets Canadian approval for implantable vagus nerve stimulation device:
This article was originally published in Clinica
Cyberonics has received approval from the Canadian Health protection Branch to market its NeuroCybernetic prosthesis, an implantable device which controls epilepsy by stimulating the vagus nerve. Cyberonics, based in Webster, Texas, estimates that more than 600,000 epileptics worldwide who do not respond to conventional drug therapy or surgery could benefit from the prosthesis.
You may also be interested in...
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.